Synexus ‘best-in-class’ solution offers unrivalled control and visibility of clinical trial lifecycle

Clinical trials budgets run into hundreds of millions of dollars. Therefore the importance of effective clinical trial management cannot be overestimated. Understanding and predicting the exact performance of a large phase III trial can be a daunting and challenging task. Systems previously available to the market follow the accrual method which has a number of limitations. Not least the lack of flexibility and forecasting enabling the entire enrolment picture to be modelled. The new system provides a consolidated view facilitating communication across all stakeholders.

Combined with the administrative burden the increasingly complex environment is having a further impact on human resource costs due to the regulatory authorities' need for more data. For an industry which is already struggling with increasing costs this is an unwelcome burden.

The IBM solution which has been developed in partnership with Synexus has a number of far reaching benefits. The best-in-class solution will further differentiate the Synexus' model as an example of innovation which adds significant value. Amongst other benefits the solution will enable Synexus to know whether it is forecasting sufficient patient numbers to meet study goals, whether patient are being enrolled fast enough to meet end points, which Centres are underperforming, whether there is adequate cost/performance balance and how much it will cost to get enrolment back on target.